The DOI matches its Crossref record; 77 of the 81 references it cites were found in a registry or an index.
9. Pharmacologic Approaches to Glycemic Treatment: Standards of Medical Care in Diabetes—2019
Abstract
The American Diabetes Association (ADA) “Standards of Medical Care in Diabetes” includes ADA’s current clinical practice recommendations and is intended to provide the components of diabetes care, general treatment goals and guidelines, and tools to evaluate quality of care. Members of the ADA Professional Practice Committee, a multidisciplinary expert committee, are responsible for updating the Standards of Care annually, or more frequently as warranted. For a detailed description of ADA standards, statements, and reports, as well as the evidence-grading system for ADA’s clinical practice recommendations, please refer to the Standards of Care Introduction. Readers who wish to comment on the Standards of Care are invited to do so at professional.diabetes.org/SOC.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Although SGLT2 inhibitor use was not incorporated into American Diabetes Association guidelines until 2019,48”
From Association of race/ethnicity, gender, and socioeconomic status with sodium-glucose cotransporter 2 inhibitor use among patients with diabetes in the US (2021) · cites this paper as [48]
Citations
Cites
Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes
Zinman, B., Wanner, C., Lachin, J. M., Fitchett, D., Bluhmki, E., Hantel, S., Mattheus, M., Devins, T., Johansen, O. E., Woerle, H. J., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504720 · Cited by 12,315
Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes
Neal, B., Perkovic, V., Mahaffey, K. W., de Zeeuw, D., Fulcher, G., Erondu, N., Shaw, W., Law, G., Desai, M., & Matthews, D. R. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1611925 · Cited by 7,830
10-year follow-up of intensive glucose control in type 2 diabetes
Holman, R. R., Paul, S. K., Bethel, M. A., Matthews, D. R., & Neil, H. A. W. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0806470 · Cited by 7,751 · cited 1×
“Metformin is effective and safe, is inexpensive, and may reduce risk of cardiovascular events and death (40).”
Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes
Marso, S. P., Daniels, G. H., Brown-Frandsen, K., Kristensen, P., Mann, J. F. E., Nauck, M. A., Nissen, S. E., Pocock, S., Poulter, N. R., Ravn, L. S., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1603827 · Cited by 7,629
Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes
Marso, S. P., Bain, S. C., Consoli, A., Eliaschewitz, F. G., Jódar, E., Leiter, L. A., Lingvay, I., Rosenstock, J., Seufert, J., Warren, M. L., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1607141 · Cited by 6,900
Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes
(2005) · New England Journal of Medicine · doi:10.1056/nejmoa052187 · Cited by 5,138
Davies, M. J., D’Alessio, D. A., Fradkin, J., Kernan, W. N., Mathieu, C., Mingrone, G., Rossing, P., Tsapas, A., Wexler, D. J., & Buse, J. B. (2018) · Diabetes Care · doi:10.2337/dci18-0033 · Cited by 3,518
Riddle (2003) · doi:10.2337/diacare.26.11.3080 · Cited by 1,479
Maruthur, N. M., Tseng, E., Hutfless, S., Wilson, L. M., Suarez-Cuervo, C., Berger, Z., Chu, Y., Iyoha, E., Segal, J. B., & Bolen, S. (2016) · Annals of Internal Medicine · doi:10.7326/m15-2650 · Cited by 682
Threshold-based insulin-pump interruption for reduction of hypoglycemia
Bergenstal, R. M., Klonoff, D. C., Garg, S. K., Bode, B. W., Meredith, M., Slover, R. H., Ahmann, A. J., Welsh, J. B., Lee, S. W., & Kaufman, F. R. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1303576 · Cited by 652
Research works printed but not linked: 6
- Peters, 2013, American Diabetes Association/JDRF Type 1 Diabetes Sourcebook
- Chiang, 2014, Type 1 diabetes through the life span: a position statement of the American Diabetes Association
- Lexicon Pharmaceuticals . FDA to review ZynquistaTM (sotagliflozin) as potential treatment for type 1 diabetes [Internet], 2018. Available from http://www.lexpharma.com/media-center/news/673-fda-to-review-zynquista-sotagliflozin-as-potential-treatment-for-type-1-diabetes. Accessed 30 September 2018
- Institute for Clinical and Economic Review . Controversies in the management of patients with type 2 diabetes [Internet], December 2014. Available from https://icer-review.org/wp-content/uploads/2015/03/CEPAC-T2D-Final-Report-December-22.pdf. Accessed 9 November 2018
- Lipska, 2018, Association of initiation of basal insulin analogs vs neutral protamine Hagedorn insulin with hypoglycemia-related emergency department visits or hospital admissions and with glycemic control in patients with type 2 diabetes, 53
- Lipska, 2017, Human insulin for type 2 diabetes: an effective, less-expensive option, 23
Cited by
Silver nanoparticles: Synthesis, medical applications and biosafety
Xu, L., Wang, Y.-Y., Huang, J., Chen, C.-Y., Wang, Z.-X., & Xie, H. (2020) · Theranostics · doi:10.7150/thno.45413 · Cited by 1,315
Tan, Y., Zhang, Z., Zheng, C., Wintergerst, K. A., Keller, B. B., & Cai, L. (2020) · Nature Reviews Cardiology · doi:10.1038/s41569-020-0339-2 · Cited by 835
Benefits of Metformin in Attenuating the Hallmarks of Aging
Kulkarni, A. S., Gubbi, S., & Barzilai, N. (2020) · Cell Metabolism · doi:10.1016/j.cmet.2020.04.001 · Cited by 766
Palmer, S. C., Tendal, B., Mustafa, R. A., Vandvik, P. O., Li, S., Hao, Q., Tunnicliffe, D., Ruospo, M., Natale, P., Saglimbene, V., et al. (2021) · BMJ · doi:10.1136/bmj.m4573 · Cited by 679
Rodbard, H. W., Rosenstock, J., Canani, L. H., Deerochanawong, C., Gumprecht, J., Lindberg, S. Ø., Lingvay, I., Søndergaard, A. L., Treppendahl, M. B., Montanya, E., et al. (2019) · Diabetes Care · doi:10.2337/dc19-0883 · Cited by 463
Flory, J., & Lipska, K. (2019) · JAMA · doi:10.1001/jama.2019.3805 · Cited by 453
Capehorn, M. S., Catarig, A.-M., Furberg, J. K., Janez, A., Price, H. C., Tadayon, S., Vergès, B., & Marre, M. (2020) · Diabetes & Metabolism · doi:10.1016/j.diabet.2019.101117 · Cited by 412
Clinical Use of DPP-4 Inhibitors
Gallwitz, B. (2019) · Frontiers in Endocrinology · doi:10.3389/fendo.2019.00389 · Cited by 374
Badmus, O. O., Hillhouse, S. A., Anderson, C. D., Hinds, T. D., & Stec, D. E. (2022) · Clinical Science · doi:10.1042/cs20220572 · Cited by 370
“Also, its long-term use has been linked with vitamin B12 deficiency [15,90].”
BackgroundEberly, L. A., Yang, L., Eneanya, N. D., Essien, U., Julien, H., Nathan, A. S., Khatana, S. A. M., Dayoub, E. J., Fanaroff, A. C., Giri, J., et al. (2021) · JAMA Network Open · doi:10.1001/jamanetworkopen.2021.6139 · Cited by 350
Furtado, R. H. M., Bonaca, M. P., Raz, I., Zelniker, T. A., Mosenzon, O., Cahn, A., Kuder, J., Murphy, S. A., Bhatt, D. L., Leiter, L. A., et al. (2019) · Circulation · doi:10.1161/circulationaha.119.039996 · Cited by 329
Zinman, B., Aroda, V. R., Buse, J. B., Cariou, B., Harris, S. B., Hoff, S. T., Pedersen, K. B., Tarp-Johansen, M. J., Araki, E., PIONEER 8 Investigators, et al. (2019) · Diabetes Care · doi:10.2337/dc19-0898 · Cited by 300
SGLT2 Inhibitors: A Review of Their Antidiabetic and Cardioprotective Effects
Tentolouris, A., Vlachakis, P., Tzeravini, E., Eleftheriadou, I., & Tentolouris, N. (2019) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph16162965 · Cited by 300
Dahlén, A. D., Dashi, G., Maslov, I., Attwood, M. M., Jonsson, J., Trukhan, V., & Schiöth, H. B. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.807548 · Cited by 275
Dapagliflozin: A Review in Type 2 Diabetes
Dhillon, S. (2019) · Drugs · doi:10.1007/s40265-019-01148-3 · Cited by 243
New frontiers in the treatment of type 1 diabetes
Warshauer, J. T., Bluestone, J. A., & Anderson, M. S. (2020) · Cell Metabolism · doi:10.1016/j.cmet.2019.11.017 · Cited by 259
Treatments for NAFLD: State of Art
Mantovani, A., & Dalbeni, A. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22052350 · Cited by 202
Makrilakis, K. (2019) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph16152720 · Cited by 216
Mucoadhesive carriers for oral drug delivery
Kumar, R., Islam, T., & Nurunnabi, M. (2022) · Journal of Controlled Release · doi:10.1016/j.jconrel.2022.09.024 · Cited by 187
Strain, W. D., Down, S., Brown, P., Puttanna, A., & Sinclair, A. (2021) · Diabetes Therapy · doi:10.1007/s13300-021-01035-9 · Cited by 194
Susceptibility for Some Infectious Diseases in Patients With Diabetes: The Key Role of Glycemia
Chávez-Reyes, J., Escárcega-González, C. E., Chavira-Suárez, E., León-Buitimea, A., Vázquez-León, P., Morones-Ramírez, J. R., Villalón, C. M., Quintanar-Stephano, A., & Marichal-Cancino, B. A. (2021) · Frontiers in Public Health · doi:10.3389/fpubh.2021.559595 · Cited by 181
Bonner, R., Albajrami, O., Hudspeth, J., & Upadhyay, A. (2020) · Primary Care: Clinics in Office Practice · doi:10.1016/j.pop.2020.08.004 · Cited by 177
Vieira, R., Souto, S. B., Sánchez-López, E., López Machado, A., Severino, P., Jose, S., Santini, A., Fortuna, A., García, M. L., Silva, A. M., et al. (2019) · Pharmaceuticals · doi:10.3390/ph12040152 · Cited by 188
Extraglycemic Effects of SGLT2 Inhibitors: A Review of the Evidence
Bonora, B. M., Avogaro, A., & Fadini, G. P. (2020) · Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy · doi:10.2147/dmso.s233538 · Cited by 177
Oxidative stress-mediated beta cell death and dysfunction as a target for diabetes management
Dinić, S., Arambašić Jovanović, J., Uskoković, A., Mihailović, M., Grdović, N., Tolić, A., Rajić, J., Đorđević, M., & Vidaković, M. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.1006376 · Cited by 165
Diabetes and Cancer: Cancer Should Be Screened in Routine Diabetes Assessment
Suh, S., & Kim, K.-W. (2019) · Diabetes & Metabolism Journal · doi:10.4093/dmj.2019.0177 · Cited by 185
US Emergency Department Visits Attributed to Medication Harms, 2017-2019
Budnitz, D. S., Shehab, N., Lovegrove, M. C., Geller, A. I., Lind, J. N., & Pollock, D. A. (2021) · JAMA · doi:10.1001/jama.2021.13844 · Cited by 178
An overview of GLP-1 agonists and recent cardiovascular outcomes trials
Sheahan, K. H., Wahlberg, E. A., & Gilbert, M. P. (2020) · Postgraduate Medical Journal · doi:10.1136/postgradmedj-2019-137186 · Cited by 194
“16 All of the following CVOTs presented here have been industry funded trials, and all are multicentre, double-blinded, randomised, placebo-controlled trials.”
BackgroundRSSDI-ESI clinical practice recommendations for the management of type 2 diabetes mellitus 2020
Madhu, S., Chawla, R., Makkar, B., Ghosh, S., Saboo, B., & Kalra, S. (2020) · Indian Journal of Endocrinology and Metabolism · doi:10.4103/ijem.ijem_225_20 · Cited by 167
DPP-4 inhibitors for treating T2DM - hype or hope? an analysis based on the current literature
Saini, K., Sharma, S., & Khan, Y. (2023) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2023.1130625 · Cited by 205
An Effective Model of Diabetes Care and Education: Revising the AADE7 Self-Care Behaviors ®
American Association of Diabetes Educators (2020) · The Diabetes Educator · doi:10.1177/0145721719894903 · Cited by 184
Metformin, Macrophage Dysfunction and Atherosclerosis
Feng, X., Chen, W., Ni, X., Little, P. J., Xu, S., Tang, L., & Weng, J. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.682853 · Cited by 164
Cheng, X., Liu, Y.-M., Li, H., Zhang, X., Lei, F., Qin, J., Chen, Z., Deng, K., Lin, L., Chen, M., et al. (2020) · Cell Metabolism · doi:10.1016/j.cmet.2020.08.013 · Cited by 163
Oral Semaglutide: A Review of the First Oral Glucagon-Like Peptide 1 Receptor Agonist
Bucheit, J. D., Pamulapati, L. G., Carter, N., Malloy, K., Dixon, D. L., & Sisson, E. M. (2020) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2019.0185 · Cited by 156
“6 With regard to weight, SGLT-2 inhibitors have also shown the propensity to facilitate weight loss in patients with T2DM, but greater effects are associated with subcutaneous semaglutide.”
Management of hypoglycemia in older adults with type 2 diabetes
Freeman, J. S. (2019) · Postgraduate Medicine · doi:10.1080/00325481.2019.1578590 · Cited by 169
2020 Clinical practice guidelines for Acute coronary syndrome without ST segment elevation
Барбараш, О. Л., Duplyakov, D. V., Zateischikov, D. A., Панченко, Е. П., Shakhnovich, R. M., Yavelov, I. S., Yakovlev, A. N., Sa, A., Alekyan, B. G., Викторович, А. М., et al. (2021) · Russian Journal of Cardiology · doi:10.15829/1560-4071-2021-4449 · Cited by 149
Novel therapies with precision mechanisms for type 2 diabetes mellitus
Perreault, L., Skyler, J. S., & Rosenstock, J. (2021) · Nature Reviews Endocrinology · doi:10.1038/s41574-021-00489-y · Cited by 155
Management of Type 2 Diabetes: Current Strategies, Unfocussed Aspects, Challenges, and Alternatives
Borse, S., Chhipa, A. S., Sharma, V., Singh, D. P., & Nivsarkar, M. (2020) · Medical Principles and Practice · doi:10.1159/000511002 · Cited by 172
Adverse drug reactions of GLP-1 agonists: A systematic review of case reports
Shetty, R., Basheer, F. T., Poojari, P. G., Thunga, G., Chandran, V. P., & Acharya, L. D. (2022) · Diabetes & Metabolic Syndrome: Clinical Research & Reviews · doi:10.1016/j.dsx.2022.102427 · Cited by 145
Lo, K. B., Gul, F., Ram, P., Kluger, A. Y., Tecson, K. M., McCullough, P. A., & Rangaswami, J. (2019) · Cardiorenal Medicine · doi:10.1159/000503919 · Cited by 139
Barengolts, E. I., Smith, E. D., Reutrakul, S., Tonucci, L. B., & Anothaisintawee, T. (2019) · Nutrients · doi:10.3390/nu11030671 · Cited by 127
Gong, J., Ye, C., Ran, J., Xiong, X., Fang, X., Zhou, X., Yi, Y., Lu, X., Wang, J., Xie, C., et al. (2023) · ACS Nano · doi:10.1021/acsnano.3c02407 · Cited by 124
McCoy, R. G., Dykhoff, H. J., Sangaralingham, L., Ross, J. S., Karaca-Mandic, P., Montori, V. M., & Shah, N. D. (2019) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2019.0213 · Cited by 122
Demaré, S., Kothari, A., Calcutt, N. A., & Fernyhough, P. (2020) · Expert Review of Neurotherapeutics · doi:10.1080/14737175.2021.1847645 · Cited by 125
Muscogiuri, G., Barrea, L., Faggiano, F., Maiorino, M. I., Parrillo, M., Pugliese, G., Ruggeri, R. M., Scarano, E., Savastano, S., Colao, A., et al. (2021) · Journal of Endocrinological Investigation · doi:10.1007/s40618-021-01574-9 · Cited by 119
Zahra, U., Saeed, A., Fattah, T. A., Flörke, Ü., & Erben, M. F. (2022) · RSC Advances · doi:10.1039/d2ra01781d · Cited by 118
A review of phenformin, metformin, and imeglimin
Yendapally, R., Sikazwe, D., Kim, S. S., Ramsinghani, S., Fraser‐Spears, R., Witte, A. P., & Viola, B. L. (2020) · Drug Development Research · doi:10.1002/ddr.21636 · Cited by 131
Methodological considerations when analysing and interpreting real-world data
Stürmer, T., Wang, T., Golightly, Y. M., Keil, A. P., Lund, J. L., & Funk, M. J. (2019) · Rheumatology · doi:10.1093/rheumatology/kez320 · Cited by 116
Hypoglycemia in patient with type 2 diabetes treated with insulin: it can happen
Heller, S. R., Peyrot, M. F., Oates, S. K., & Taylor, A. D. (2020) · BMJ Open Diabetes Research & Care · doi:10.1136/bmjdrc-2020-001194 · Cited by 111
Muthiah, M. D., Han, N. C., & Sanyal, A. J. (2021) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14521 · Cited by 114
Engler, C., Leo, M., Pfeifer, B. E., Juchum, M., Chen-Koenig, D., Pölzl, K., Schoenherr, H., Vill, D., Oberdanner, J., Eisendle, E., et al. (2020) · BMJ Open Diabetes Research & Care · doi:10.1136/bmjdrc-2020-001279 · Cited by 116
Can Metformin Exert as an Active Drug on Endothelial Dysfunction in Diabetic Subjects
Salvatore, T., Pafundi, P. C., Galiero, R., Rinaldi, L., Caturano, A., Vetrano, E., Aprea, C., Albanese, G., Di Martino, A., Ricozzi, C., et al. (2020) · Biomedicines · doi:10.3390/biomedicines9010003 · Cited by 97
Metformin in pregnancy and risk of adverse long-term outcomes: a register-based cohort study
Brand, K. M. G., Saarelainen, L., Sõnajalg, J., Boutmy, E., Foch, C., Vääräsmäki, M., Morin-Papunen, L. C., Schlachter, J., CLUE Study Group, Hakkarainen, K. M., et al. (2022) · BMJ Open Diabetes Research & Care · doi:10.1136/bmjdrc-2021-002363 · Cited by 97
Emerging glucagon-like peptide 1 receptor agonists for the treatment of obesity
Jepsen, M. M., & Christensen, M. B. (2021) · Expert Opinion on Emerging Drugs · doi:10.1080/14728214.2021.1947240 · Cited by 96
SGLT2 Inhibitors: Nephroprotective Efficacy and Side Effects
Garofalo, C., Borrelli, S., Liberti, M., Andreucci, M., Conte, G., Minutolo, R., Provenzano, M., & Nicola, L. D. (2019) · Medicina · doi:10.3390/medicina55060268 · Cited by 105
Mohan, V., Khunti, K., Chan, S. P., Filho, F. F., Tran, N. Q., Ramaiya, K. L., Joshi, S., Mithal, A., Mbaye, M. N., Nicodemus, N. A., et al. (2019) · Diabetes Therapy · doi:10.1007/s13300-019-00733-9 · Cited by 112
Colacci, M., Fralick, J., Odutayo, A., & Fralick, M. (2022) · Canadian Journal of Diabetes · doi:10.1016/j.jcjd.2021.04.006 · Cited by 94
Halabi, A., Sen, J., Huynh, Q., & Marwick, T. H. (2020) · Cardiovascular Diabetology · doi:10.1186/s12933-020-01100-w · Cited by 93
Wu, C., Ouk, M., Wong, Y. Y., Anita, N. Z., Edwards, J. D., Yang, P., Shah, B. R., Herrmann, N., Lanctôt, K. L., Kapral, M. K., et al. (2020) · Alzheimer s & Dementia · doi:10.1002/alz.12161 · Cited by 98
Tsai, S., Yang, C., Liu, W.-J., & Lee, C.-L. (2023) · EClinicalMedicine · doi:10.1016/j.eclinm.2023.101934 · Cited by 98
NAFLD and Cardiovascular Diseases: Epidemiological, Mechanistic and Therapeutic Considerations
Niederseer, D., Wernly, B., Aigner, E. S., Stickel, F., & Datz, C. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10030467 · Cited by 93
Glucagon-Like Peptide-1 Receptor Agonists in Type 2 Diabetes: Their Use and Differential Features
Lyseng-Williamson, K. A. (2019) · Clinical Drug Investigation · doi:10.1007/s40261-019-00826-0 · Cited by 87
The Pleiotropic Effects of Sodium–Glucose Cotransporter-2 Inhibitors: Beyond the Glycemic Benefit
Patel, D. K., & Strong, J. L. (2019) · Diabetes Therapy · doi:10.1007/s13300-019-00686-z · Cited by 95
Blonde, L., Rosenstock, J., Del Prato, S., Henry, R., Shehadeh, N., Frias, J., Niemoeller, E., Souhami, E., Ji, C., & Aroda, V. R. (2019) · Diabetes Care · doi:10.2337/dc19-1357 · Cited by 85
Le, P. N. B., Chaitoff, A. M., Misra‐Hebert, A. D., Ye, W., Herman, W. H., & Rothberg, M. B. (2020) · Diabetes Care · doi:10.2337/dc19-2424 · Cited by 91
Mechanism of glucose-lowering by metformin in type 2 diabetes: Role of bile acids
Sansome, D. J., Xie, C., Veedfald, S., Horowitz, M., Rayner, C. K., & Wu, T. (2020) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.13869 · Cited by 84
Leveraging the Gut to Treat Metabolic Disease
Gimeno, R. E., Briere, D. A., & Seeley, R. J. (2020) · Cell Metabolism · doi:10.1016/j.cmet.2020.02.014 · Cited by 83
Bellastella, G., Maiorino, M. I., Longo, M., Scappaticcio, L., Chiodini, P., Esposito, K., & Giugliano, D. (2020) · Stroke · doi:10.1161/strokeaha.119.027557 · Cited by 83
Barriers to prescribing glucose-lowering therapies with cardiometabolic benefits
Gao, Y., Peterson, E. D., & Pagidipati, N. J. (2020) · American Heart Journal · doi:10.1016/j.ahj.2020.03.017 · Cited by 83
Hussain, H., Green, I. R., Abbas, G., Adekenov, S. M., Hussain, W., & Ali, I. (2019) · Expert Opinion on Therapeutic Patents · doi:10.1080/13543776.2019.1655542 · Cited by 86
Engström, M. S., Leksell, J. K., Johansson, U., Borg, S., Palaszewski, B., Franzén, S., Guðbjörnsdóttir, S., & Eeg‐Olofsson, K. (2019) · Health and Quality of Life Outcomes · doi:10.1186/s12955-019-1212-z · Cited by 82
“Diabetes care continuously advances with new medical treatments, technical aids for insulin administration and the continuous monitoring of glucose levels, and skills facilitating self-management [1, 7, 29, 30].”
BackgroundYapışlar, H., & Gürler, E. B. (2024) · Biomedicines · doi:10.3390/biomedicines12091958 · Cited by 89
“These prodrugs can be modified with specific moieties, such as amino acids, folate, or sugar, which interact with renal tubular receptors for targeted uptake [152].”
BackgroundShao, S., Chang, K., Hung, M., Yang, N.-I., Chan, Y., Chen, H., Yang, Y. K., & Lai, E. C. (2019) · Cardiovascular Diabetology · doi:10.1186/s12933-019-0919-9 · Cited by 78
Human beige adipocytes for drug discovery and cell therapy in metabolic diseases
Singh, A. M., Zhang, L., Avery, J. W., Yin, A., Du, Y., Wang, H., Li, Z., Fu, H., Yin, H., & Dalton, S. (2020) · Nature Communications · doi:10.1038/s41467-020-16340-3 · Cited by 80
Current management of non‐alcoholic steatohepatitis
Muthiah, M. D., & Sanyal, A. J. (2020) · Liver International · doi:10.1111/liv.14355 · Cited by 77
SGLT2 inhibitors in patients with type 2 diabetes and renal disease: overview of current evidence
Davidson, J. A. (2019) · Postgraduate Medicine · doi:10.1080/00325481.2019.1601404 · Cited by 82
Qu, L., Liang, X., Tian, G., Zhang, G., Wu, Q., Huang, X., Cui, Y., Liu, Y., Shen, Z., Xiao, C., et al. (2021) · Diabetes Care · doi:10.2337/dc20-2109 · Cited by 75
Sex Differences in Adverse Drug Reactions of Metformin: A Longitudinal Survey Study
de Vries, S. T., Denig, P., Ekhart, C., Mol, P. G. M., & van Puijenbroek, E. (2020) · Drug Safety · doi:10.1007/s40264-020-00913-8 · Cited by 76
The use of GLP1R agonists for the treatment of type 2 diabetes in kidney transplant recipients
Kukla, A., Hill, J., Merzkani, M., Bentall, A., Lorenz, E. C., Park, W. D., D’Costa, M., Kudva, Y. C., Stegall, M. D., & Shah, P. (2020) · Transplantation Direct · doi:10.1097/txd.0000000000000971 · Cited by 73
Time to Include Nonalcoholic Steatohepatitis in the Management of Patients With Type 2 Diabetes
Cusi, K. J. (2020) · Diabetes Care · doi:10.2337/dci19-0064 · Cited by 78
Hughes, S., & Neumiller, J. J. (2019) · Clinical Diabetes · doi:10.2337/cd19-0079 · Cited by 71
Nagahisa, T., & Saisho, Y. (2019) · Diabetes Therapy · doi:10.1007/s13300-019-00680-5 · Cited by 93
Madsen, K. S., Chi, Y., Metzendorf, M.-I., Richter, B., & Hemmingsen, B. (2019) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd008558.pub2 · Cited by 70
Coco, L. D., Vergara, D., Matteis, S. D., Mensa’, E., Sabbatinelli, J., Prattichizzo, F., Bonfigli, A. R., Storci, G., Bravaccini, S., Pirini, F., et al. (2019) · Journal of Clinical Medicine · doi:10.3390/jcm8050720 · Cited by 73
Marchesini, G., Bugianesi, E., Burra, P., Marra, F., Miele, L., Alisi, A., Vajro, P., Masarone, M., Petta, S., Persico, M., et al. (2021) · Nutrition Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2021.04.028 · Cited by 70
SGLT2 Inhibitor–Induced Euglycemic Diabetic Ketoacidosis: A Case Report
Wang, K. M., & Isom, R. T. (2020) · Kidney Medicine · doi:10.1016/j.xkme.2019.12.006 · Cited by 70
Role of dipeptidyl peptidase 4 inhibitors in the new era of antidiabetic treatment
Florentin, M., Kostapanos, M. S., & Papazafiropoulou, A. K. (2022) · World Journal of Diabetes · doi:10.4239/wjd.v13.i2.85 · Cited by 75
Şahin, İ., Bakıner, O., Demir, T., Sari, R., & Atmaca, A. A. (2024) · Diabetes Therapy · doi:10.1007/s13300-024-01612-8 · Cited by 76
“…guidelines and consensus reports, the standard treatment for T2D involves use of metformin in conjunction with lifestyle changes as first-line glucose lowering therapy, while early and prompt transition to combination therapies is recommended in case of failure to achieve glycemic control [22–24].”
BackgroundHaahr, H., & Heise, T. (2019) · Clinical Pharmacokinetics · doi:10.1007/s40262-019-00834-5 · Cited by 50
Bell, K. J., Fio, C. Z., Twigg, S. M., Duke, S., Fulcher, G. R., Alexander, K., McGill, M. J., Wong, J., Brand-Miller, J. C., & Steil, G. M. (2019) · Diabetes Care · doi:10.2337/dc19-0687 · Cited by 67
Long-term observational study on the impact of GLP-1R agonists on lung function in diabetic patients
Rogliani, P., Matera, M. G., Calzetta, L., Hanania, N. A., Page, C. P., Rossi, I., Andreadi, A., Galli, A., Coppola, A., Cazzola, M., et al. (2019) · Respiratory Medicine · doi:10.1016/j.rmed.2019.06.015 · Cited by 66
Carbone, S., Billingsley, H., Canada, J. M., Bressi, E., Rotelli, B., Kadariya, D., Dixon, D. L., Markley, R., Trankle, C. R., Cooke, R. H., et al. (2020) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.3335 · Cited by 68
Averkov, O. V., HARUTYUNYAN, G., Duplyakov, D. V., Константинова, Е. В., Nikulina, N. N., Shakhnovich, R. M., Yavelov, I. S., Yakovlev, A. N., Abugov, S. A., Alekyan, B. G., et al. (2025) · Russian Journal of Cardiology · doi:10.15829/1560-4071-2025-6319 · Cited by 77
Bhagavathula, A. S., Vidyasagar, K., & Tesfaye, W. H. (2021) · Pharmaceuticals · doi:10.3390/ph14100991 · Cited by 65
Gözel, N., & Kılınç, F. (2020) · Endokrynologia Polska · doi:10.5603/ep.a2020.0059 · Cited by 63
Hashem, M., Esmael, A., Nassar, A. K., & El-Sherif, M. (2021) · Scientific Reports · doi:10.1038/s41598-021-81631-8 · Cited by 63
Albogami, Y., Cusi, K. J., Daniels, M. J., Wei, Y. J., & Winterstein, A. G. (2021) · Diabetes Care · doi:10.2337/dc20-1794 · Cited by 63
Tankova, T. I., Senkus, E., Beloyartseva, M., Borštnar, S., Catrinoiu, D., Фролова, М. А., Hegmane, A., Janež, A., Krnić, M., Lengyel, Z., et al. (2022) · Cancers · doi:10.3390/cancers14071598 · Cited by 63
Simplifying Complex Insulin Regimens While Preserving Good Glycemic Control in Type 2 Diabetes
Taybani, Z. J., Bótyik, B., Katkó, M., Gyimesi, A., & Várkonyi, T. T. (2019) · Diabetes Therapy · doi:10.1007/s13300-019-0673-8 · Cited by 62
Long-Term Effectiveness of Liraglutide for Weight Management and Glycemic Control in Type 2 Diabetes
Mirabelli, M., Chiefari, E., Caroleo, P., Arcidiacono, B., Corigliano, D. M., Giuliano, S., Brunetti, F. S., Tanyolaç, S., Foti, D. P., Puccio, L., et al. (2019) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph17010207 · Cited by 61
Metadata
- Authors
- American Diabetes Association
- Corresponding author
- American Diabetes Association
- Venue
- Diabetes Care
- Publisher
- American Diabetes Association
- Published
- 2018-12-07
- Volume
- 42
- Issue
- Supplement_1
- Pages
- S90-S102
- ISSN
- 0149-5992 (ISSN-L)
- 1935-5548
- OpenAlex
- W4212810717
- Cited by
- 739
- References
- 81
- Citations by year
- 2026: 12 · 2025: 28 · 2024: 30 · 2023: 47 · 2022: 69 · 2021: 126 · 2020: 246 · 2019: 181
- FWCI
- 21.27
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Diabetes Care (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Education
- Keywords
- glycemic control, pharmacotherapy, antidiabetic drugs, treatment goals, quality of care, clinical guidelines
- MeSH terms
- Blood Glucose, Diabetes Mellitus, Glycated Hemoglobin, Humans, Hypoglycemic Agents, Societies, Medical, United States, Practice Guidelines as Topic, Standard of Care
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.